Sagimet Biosciences
SGMT
51 hedge funds and large institutions have $76.2M invested in Sagimet Biosciences in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 7 closing their positions.
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
6% more funds holding
Funds holding: 48 → 51 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.26% less ownership
Funds ownership: 72.88% → 67.62% (-5.3%)
41% less capital invested
Capital invested by funds: $130M → $76.2M (-$54M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$3.02M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
+$1.68M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.16M |
| 4 |
BlackRock
New York
|
+$302K |
| 5 |
State Street
Boston,
Massachusetts
|
+$236K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$4.53M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.54M |
| 3 |
RI
RTW Investments
New York
|
-$3.52M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.74M |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$1.28M |
SGMT Hedge Fund Activity: Q4 2023 in Review
51 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q4 2023, worth a combined $76.2M — down 41% from $130M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new SGMT positions and 7 closed out — a net gain of 4 holders — while 17 added to existing stakes and 9 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $3.02M. The largest seller was VR Adviser, exiting entirely with an estimated $4.53M sold.
- 51 institutional investors held Sagimet Biosciences (SGMT) as of Q4 2023, up from 48 in Q3 2023.
- Funds reported $76.2M of Sagimet Biosciences stock for Q4 2023, down 41% quarter-over-quarter.
- 11 funds opened new Sagimet Biosciences positions in Q4 2023 and 7 closed out, a net change of +4 holders.
- The largest Sagimet Biosciences buyer in Q4 2023 was Baker Bros. Advisors, an estimated $3.02M added.
- The largest Sagimet Biosciences seller in Q4 2023 was VR Adviser, an estimated $4.53M sold.
Based on aggregated 13F filings for Q4 2023.